120,000 patients ‘left in the dark’ over cancer treatment
Macmillan Cancer Support has cited “soaring” pressures on the NHS, leaving staff table to provide the appropriate care for patients.
Read More
Tag: left in the dark
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
